Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-26 @ 2:08 AM
Study NCT ID:
NCT04209205
Status:
COMPLETED
Last Update Posted:
2025-05-16
First Post:
2019-10-30
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-01-29
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-17
Completion Date Type:
ACTUAL
First Submit Date:
2019-10-30
First Submit QC Date:
None
Study First Post Date:
2019-12-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-05-08
Results First Submit QC Date:
None
Results First Post Date:
2024-04-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-04-26
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2025-05-14
Last Update Post Date:
2025-05-16
Last Update Post Date Type:
ACTUAL